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Virginie Mignaux5, Nadia Tillouche6 and François Fourrier1Abstract
Background: Even in developed countries, severe specific pregnancy complications may occur in the immediate
postpartum period and require admission to the ICU. The characteristics and risk factors of acute renal failure (ARF)
induced by these complications and their treatments are not well known.
Methods: We performed a retrospective multicenter study in three intensive care departments linked to level III
maternity wards in the north of France. All patients admitted to ICU for postpartum complications over a 5-year
period (2008 to 2012) were included. Clinical and biological data, delivery characteristics, type of complications, and
treatments were compared by univariate and multivariate analyses according to the occurrence and severity of ARF.
Results: One hundred eighty-two patients admitted to ICU for postpartum complications were included in the
study. Sixty-eight patients (37%) developed an ARF: 49 with a low or medium severity and 19 with a severe ARF
requiring renal replacement therapy. Hemolysis, elevated liver enzyme, and low platelet count (HELLP) syndrome on
its own (p = 0.047) or combined with postpartum haemorrhage (p = 0.003), previous treatment by hyperoncotic
albumin infusion (p = 0.001) and blockade of fibrinolysis by tranexamic acid (p = 0.03), was associated with secondary
ARF. By multivariate analysis, the only independent factors were the association of HELLP syndrome with postpartum
haemorrhage and the use of hyperoncotic albumin infusion.
Conclusions: HELLP syndrome associated with postpartum haemorrhage induces a high risk of ARF in the complicated
postpartum setting. A particular attention should be given to treatments that could worsen the kidney function in that
situation.
Keywords: Pregnancy; Postpartum complications; Intensive care; Acute renal failure; HELLP syndrome; Postpartum
haemorrhage; Hyperoncotic albumin; Tranexamic acidBackground
Maternal mortality has significantly decreased over the
last decades. Nevertheless, even today, the short period
that immediately follows childbirth may be complicated
thus putting the mother's life at stake. In the whole
pregnant population, approximately 0.2% of women will
require critical care, and this percentage can reach 1% in
medium and low resource countries [1,2]. The main
causes of intensive care unit (ICU) admission are post-
partum hemorrhage, preeclampsia and related diseases,
and sepsis [3,4].* Correspondence: marie.jonard@chru-lille.fr
1Servie de Réanimation Polyvalente, Centre de Réanimation, Hôpital Roger
Salengro, CHRU, 2 Avenue Oscar Lambret, Lille Cedex 59037, France
Full list of author information is available at the end of the article
© 2014 Jonard et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pAcute renal failure (ARF) is rare in that setting. Its in-
cidence has decreased from 1/3,000 to 1/20,000 between
the 1960's and today [5]. Nevertheless, it remains an im-
portant source of morbidity and mortality. ARF is more
often due to pregnancy-related diseases. The first peak
of incidence, during the first trimester, is dominated by
infection and illegal abortion in low-resource countries.
The second peak occurs during the third trimester and
is related to preeclampsia, the hemolysis, elevated liver
enzyme, and low platelet count (HELLP) syndrome, acute
fatty liver disease of pregnancy, or postpartum hemorrhage.
Classically, it is believed that ARF occurs in 1% of se-
vere preeclampsia, 3% to 15% of HELLP syndromes [6,7]
and 60% in acute fatty liver disease of pregnancy [8],
with preeclampsia and HELLP syndrome covering 40%n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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studies whether the coagulopathy induced by the HELLP
syndrome could increase the magnitude of postpartum
hemorrhage or, conversely, whether uterine hemorrhage
could aggravate the thrombotic microangiopathy of the
HELLP syndrome and subsequent renal ischemia. Their
association might represent a peculiar risk of ARF in the
postpartum setting.
The aim of our study was to identify the risk of ARF
induced by postpartum hemorrhage, preeclampsia, HELLP
syndrome, and their association in patients admitted to
the ICU in the postpartum period. We also tried to docu-
ment in this setting the possible impact of the treatments
used to control hemorrhage and arterial hypertension.Methods
We performed a multicenter observational study over
a 5-year period in three intensive care departments at-
tached to level III maternity wards in the north of France.
In the geographic area of these three hospitals, obstetrical
care is strictly organized, and women developing severe
postpartum complications are transferred to these three
referral centers comprising a level III maternity ward and
one ICU.
All patients admitted to the ICU immediately after child-
birth were included in our study. Patients admitted to the
ICU during pregnancy or admitted for non-pregnancy re-
lated disease were excluded (see flow chart, Figure 1).
Case notes were retrospectively analyzed. All observations
were reviewed anonymously. Therefore, informed consent198 Patients adm
192 postpartum inc
6 pregnant excluded: - 3 preeclampsia still pregnant
- 3 pregnant women infected with 
H1N1 influenzae virus with ARDS
182 patients incl
10 excluded : - 3 died in ICU (amniotic embolism
with massive hemorrhage)
- 7 had incomplete records







Figure 1 Flowchart of the cohort.was not sought for in accordance to the French clinical
research guidelines.
Definitions and criteria
The main objective of our study was to compare women
with ARF and those without to document the risk factors
of ARF in the complicated postpartum period.
ARF was diagnosed when serum creatinine levels were
89 μmol/L or greater, from delivery until the sixth day
postpartum. Patients were subdivided into the following
three groups based on the highest value of serum creatinine
and on renal replacement therapy requirement:
 The ARF 1 group, with serum creatinine levels
between 89 and 261 μmol/L;
 The ARF 2 group, when serum creatinine was
greater or equal to 262 μmol/L but patients did not
require renal replacement therapy; and
 The ARF 3 group, when patients required renal
replacement therapy.
The risk, injury, failure, loss of function, and end-stage
renal disease (RIFLE) score was also calculated on ad-
mission and discharge for follow-up [10,11]. Medium
and long-term outcome (1 to 5 years) was determined
via the North of France Kidney Registry related to preg-
nancy [Néphronor* registry] and via the patient's general
practitioner.
Postpartum hemorrhage was diagnosed when blood
loss in the first 24 h after delivery was greater thanitted to the ICU
luded in the cohort
uded in the study
114 patients without ARF
ts in the ARF group 1 
9-261 µmol/L)
s in the ARF group 3
placement therapy)
in the ARF group 2 
 but do not require dialysis)
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cesarean section [12].
Preeclampsia was diagnosed if blood pressure was ≥140/
90 mmHg and proteinuria ≥300 mg/day at anytime from
week 20 of gestation [13]. HELLP syndrome was defined
by the combination of thrombocytopenia (<100 G/L),
elevated liver enzymes (AST >70 UI/L), and hemolysis
[14]. Hemolysis was defined by a bilirubin >12 mg/L,
LDH >600 UI/L, haptoglobin <0.5 mg/L, and the
presence of more than 0.5% schizocytes. In patients who
presented a postpartum hemorrhage and/or needed
platelet transfusion, the decrease in platelet count was
not used as diagnostic criteria of HELLP syndrome,
except when the HELLP syndrome had clearly preceded
the hemorrhagic complication.
Criteria for diagnosis of acute fatty liver disease of
pregnancy include six or more of the following (Swansea
criteria): vomiting, abdominal pain, polydipsia/polyuria,
encephalopathy, elevated bilirubin (>14 μmol/L),
hypoglycemia (<4 μmol/L), elevated blood uric acid
(>340 μmol/L), leukocytosis (>11 × 109/L), ascites or
bright liver on ultrasound scan, elevated transaminases
(aspartate aminotransferase or alanine aminotransferase
>42 IU/L), elevated ammonia (>47 μmol/L), renal
impairment (creatinine >150 μmol/L), and coagulopathy
(prothrombin time >14 s or activated partial
thromboplastin time >34 s)[15].
The possible occurrence of kidney hypoperfusion was
considered when mean arterial pressure was lower than
60 mmHg on two separate occasions between delivery
and the fourth day after. Patients receiving vasoactive
support (norepinephrine) after severe postpartum
haemorrhage were considered hypotensive.
The diagnosis of severe sepsis used the definitions of
the American College of Chest Physicians and the
Society of Critical Care Medicine [16].
The patient's severity was assessed by the SAPS II score
during the first 24 h after admission in the ICU [17].
The severity of coagulopathy was assessed by the
International Society of Thrombosis and Haemostasis
(ISTH) disseminated intravascular coagulation (DIC)
score [18]. Due to an expected low number of patients
developing overt DIC, an ISTH score of >3 was
considered as witness of severe coagulation disorders.
All drugs received from delivery until the fourth day
postpartum were considered with special attention
given to the use and amount of the following:
 Plasma volume expanders: fluids (crystalloids, artificial
colloids, 4% and 20% hyperoncotic serum albumin),
blood products (packed red cells, platelets, fresh
plasma, and fibrinogen)
 Antifibrinolytic: tranexamic acid
 Anti-hypertensive drugs, diuretics, angiotensin-
converting enzyme (ACE) inhibitors Nephrotoxic agents: aminoglycosides and radio-
contrast media.
Statistical analysis
Statistical analysis was performed using SAS software
(SAS Institute, Cary, NC, 25513; version 9.3). Results are
given as number, mean, median, and interquartile range
for quantitative variables, and percentages for nominal
variables.
Comparisons between groups were done using Student's
t-test and Mann-Whitney's U test when appropriate.
When more that two groups were present, a Kruskal-
Wallis one-way analysis of variance was performed. Com-
parisons were performed using either a chi-squared test or
Fisher's exact test when appropriate.
First of all, clinical and biological characteristics were
compared according to the occurrence of ARF. Regarding
pregnancy-related diseases, the frequency of ARF was
compared according to the development of preeclampsia,
HELLP syndrome, and postpartum hemorrhage and to
their association (preeclampsia + postpartum hemorrhage;
HELLP + postpartum hemorrhage). Differences in all re-
corded variables were compared by univariate analysis.
Then, to isolate independent risk factors of ARF, all vari-
ables identified in the univariate analysis with a p <0.2 and
less than 20% missing data were included in a multivariate
analysis followed by a bootstrap analysis. Odd ratios for
ARF and their 95% confidence intervals (95%) were deter-
mined with p <0.05 taken as the level of significance.
Results
During the 5 years of the study, 198 patients were admit-
ted to ICU in the postpartum period, with 182 included
in the study (see flowchart in Figures 1 and 2). During
the same period, 59,302 deliveries were included in the
pregnancy registry of the three geographic areas. There-
fore, patients admitted to the ICU for postpartum compli-
cations represented 0.33% of all deliveries in our study.
Main demographic data and causes of ICU admission are
given in Table 1 and Figure 2, respectively.
Classification and outcome of ARF (main results are
presented in Table 2)
ARF complicated the course of 68 patients (37.3%).
Among these 68 patients, 40 (59%) had a low-grade ARF
(ARF 1), 9 (13%) a medium grade (ARF 2), and 19 (28%) a
high grade (ARF 3) requiring renal replacement therapy.
According to the RIFLE classification, 20 patients in the
ARF 1 group had a RISK score on admission and had a
normal renal function on discharge. The remainder of
the group was considered as INJURY or FAILURE. They
all evolved favorably before discharge. Overall, 85% (n = 34)





(7 versus 22, NS)
With HELLP 
n=74
(34 versus 40, p = 0.047)
Without PPH 
n=20
(5 versus 15, NS)
With PPH
n=9









Figure 2 Flowchart of the 103 patients admitted in the ICU for preeclampsia. Data are given in number. Numbers in bracket represent the
number of patients with ARF versus patients without ARF and the p value between ARF and no ARF group. PPH: postpartum hemorrhage.
Jonard et al. Annals of Intensive Care 2014, 4:36 Page 4 of 11
http://www.annalsofintensivecare.com/content/4/1/36patients (12%) normalized their renal function within
1 month and one patient had a delayed recovery
(6 months).
In the ARF 2 group, the nine patients were all classified
as FAILURE according to RIFLE. On discharge, two had
completely recovered and seven still had a FAILURE
score. Among those, three normalized their function
within one month and three in 6 months. One patient
ended up with chronic kidney disease requiring dialysis.
In the ARF 3 group, except one patient who normalized
her renal function while in the ICU, the 19 patients were
considered as FAILURE on admission and on discharge.
The majority of them normalized their kidney function
between 6 to 12 months. Seven (37%) went on toTable 1 Patients' baseline characteristics
All patients n = 182
Age, yearsa 29 [26 to 34]
Number of pregnancya 2 [1 to 3]
Paritya 1 [1 to 3]
Gestational diabetes 25 (14)
Chronic hypertension 6 (3)
Gestational hypertension 13 (7)
Obesity 26 (14)
Twin gestation 11 (6)
Terma (week of gestation) 37 [33 to 39]
Antihypertensive agents before pregnancy 4 (2)
Antihypertensive agents during pregnancy 41 (23)
Cesarean delivery 128 (71)
Vaginal childbirth 53 (29)
SAPS II scorea 21 [14 to 31]
Length of stay in the ICU (days)a 3 [2 to 4]
Data are N (%) for qualitative variables. aQuantitative variables are presented as me
SAPS: simplified acute physiology score.chronic dialysis. In these seven cases, cortical necrosis
was diagnosed by kidney biopsy and/or magnetic reson-
ance imaging after discharge from the ICU to the neph-
rology ward.
No case of atypical HUS was observed in our patients.
Postpartum complications associated with ARF
Patient's characteristics and treatments are summarized
in Tables 3, 4, and 5 and Figure 2.
The frequency of ARF was different according to the
type of postpartum complications. When these complica-
tions were not associated, the frequency of ARF reached
24% in patients with preeclampsia, 30% in postpartum
hemorrhage, 46% in HELLP, and 4 of 5 with acute fattyARF group n = 68 No ARF group n = 114 p value
29 [26 to 33] 30 [25 to 34] 0.857
2 [1 to 3] 2 [1 to 3] 0.4
1 [1 to 2] 1 [1 to 3] 0.8
10 (15) 15 (13) 0.7
3 (4) 3 (3) NA
5 (7) 8 (7) 0.27
14 (21) 12 (11) 0.17
6 (9) 5 (4) 0.33
35 [33 to 39] 37 [32 to 39] 0.82
1 (1) 3 (3) NA
14 (21) 27 (23) NA
45 (62) 83 (76) 0.15
23 (34) 30 (26) 0.14
28 [17 to 36] 18 [13 to 24] <0.001
4 [3 to 7] 2 [2 to 3] <0.001
dian [interquartile range: 25th to 75th percentiles]. NA = not applicable;
Table 2 Classification of ARF and outcome
ARF 1 n = 40 ARF 2 n = 9 ARF 3 n = 19 All ARF n = 68 p value
RIFLE first day in ICU <0.0001
RISK 20 (50) 0 0 20 (29)
INJURY 13 (32) 0 0 13 (19)
FAILURE 7 (17) 9 (100) 19 (100) 35 (51)
RIFLE last day in ICU NA
RISK 5 (12) 0 0 5 (7)
INJURY 2 (5) 0 0 2 (3)
FAILURE 1 (2) 7 (78) 18 (95) 26 (38)
Normalized renal function in the ICU 32 (80) 2 (22) 1 (5) 35 (51)
Transfer to nephrology ward 1 (2) 4 (44) 16 (84) 21 (31) <0.0001
Delay of renal recovery NA
<15 days 34 (85) 2 (22) 1 (5) 37 (54)
15 days to 1 month 5 (12) 3 (33) 1 (5) 9(13)
1 month to 6 months 1 (2) 3 (33) 7 (36) 11 (16)
>6 months 0 0 3 (16) 4 (6)
>1 year or chronic renal failure 0 1 (11) 7 (37) 8 (12)
Chronic hemodialysis 0 1 (11) 2 (10) 3 (4) NA
Data are N (%). NA = not applicable.
Jonard et al. Annals of Intensive Care 2014, 4:36 Page 5 of 11
http://www.annalsofintensivecare.com/content/4/1/36liver disease of pregnancy. In the high severity ARF groups
2 and 3, nine patients among 28 had presented an isolated
postpartum hemorrhage and nine the association HELLP-
postpartum hemorrhage. The univariate analysis showed
that when isolated, preeclampsia, HELLP syndrome, and
postpartum hemorrhage were not significantly linked to
ARF.
Thirty patients developed the association HELLP
syndrome-postpartum hemorrhage. Complete data of this
subgroup are given in Table 6. The frequency of ARF was
significantly higher in patients who had presented this as-
sociation (frequency of ARF: 67%; p = 0.003). In two cases
only, the HELLP syndrome occurred in the 48 h after the
hemorrhagic event. In 28 cases, postpartum hemorrhage
occurred sequentially after completion of the HELLP
syndrome. The amount of postpartum bleeding wasTable 3 Frequency or acute renal failure according to the typ
All patients n = 182 AR
PE without HELLP 20 (11)
Eclampsia 21 (12)
AFLP 5 (3)
Isolated HELLP without PPH 44 (24)
Isolated PPH 70 (39)
Volume of bleedinga (mL) 2,500 [1,525 to 4,000] 2,00
PPH + PE without HELLP 9 (5)
PPH + HELLP 30 (17)
Data are N (%) for qualitative variables. aQuantitative variables are presented as me
acute fatty liver pregnancy; PE: preeclampsia; HELLP: hemolysis, elevated liver, andnot higher in these patients with even a trend to a lower
amount of bleeding (median 2,000 mL in isolated postpartum
hemorrhage vs 1,700 mL when postpartum hemorrhage
was associated to HELLP; p = 0.18).
Concerning the severity of coagulation disorders, pa-
tients who developed ARF had more frequently an ISTH
score greater than 3 (49 vs 32%; p = 0.034). However, in
the ARF group, the median value of the ISTH score was
not significantly different between patients with or with-
out postpartum hemorrhage (median 3.0 vs 3.0 points;
NS), with or without HELLP syndrome (3.0 ± 1.8 vs 2.7 ±
1.9; NS), and with or without their association (2.8 ± 1.5 vs
2.6 ± 2.0; NS). Among the 28 patients who developed an
ARF grade 2 or 3, seven patients only had an ISTH score
of >4, consistent with acute overt DIC. Due to this low
number, an ISTH score of >3 was entered in thee of pregnancy and delivery complications
F group n = 68 No ARF group n = 114 p value
5 (7.3) 15 (13.1) 0.225
5 (7) 16 (14) 0.172
4 (6) 1 (1) NA
14 (20.5) 30 (26.3) 0.382
21 (31) 49 (43) 0.104
0 [1,500 to 3,000] 3,000 [1,750 to 4,050] 0.035
2 (2.9) 7 (6.1) 0.335
20 (29) 10 (9) 0.0003
dian [interquartile range: 25th to 75th percentiles]. NA = not applicable; AFLP:
low platelet count syndrome; PPH: postpartum hemorrhage.
Table 4 Comparisons according to the severity of ARF (n = 68)
ARF 1 n = 40 ARF 2 n = 9 ARF 3 n = 19 p value
Age, yearsa 30 [26 to 34] 25 [21 to 28] 31 [27 to 33] 0.18
Term (week of gestation)a 37 [33 to 39] 33 [29 to 38] 37 [36 to 39] 0,2
Number of pregnancya 1 [1 to 2] 1 [1 to 1] 2 [1 to 3] 0.04
Twin gestation 2 (5) 0 4 (21) 0.087
SAPS II scorea 20 [16 to 29] 27 [21 to 29] 37 [33 to 45] <0.001
Length of ICU stay (days)a 3.5 [2 to 4.5] 5 [3 to 5] 9 [5 to 13] <0.001
All PE; n = 41 24 (60) 5 (56) 12 (63) 0.93
Whose HELLP; n = 34 19 (47) 4 (44) 11 (58) 0.77
PPH; n = 43 25 (62) 3 (33) 15 (79) 0.064
Volume of bleeding (mL)a 2,300 [1,600 to 3,000] 1,500 [750 to 4,000] 2,000 [1,500 to 3,000] NA
PPH only; n = 21 12 (30) 2 (22) 7 (37) 0.72
Hypotension; n = 11 7 (17) 0 4 (21) 0.46
PPH + HELLP; n = 20 11 (27) 1 (11) 8 (42) 0.22
ISTH score >3; n = 29 17 (46) 2 (29) 10 (67) 0.23
Data are N (%) for qualitative variables. Incidence is given in brackets considering missing data. About treatment, the incidence is related to the number of
patients who actually received the treatment. aQuantitative variables are presented as median [space interquartile range: 25th to 75th percentiles]. NA = not
applicable; SAPS: simplified acute physiology score; PE: preeclampsia; HELLP: hemolysis, elevated liver, and low platelet count syndrome; AFLP: acute fatty liver
pregnancy; ISTH = International Society on Thrombosis and Hemostasis score.
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agulation disorders.
Concerning treatments given between delivery and the
fourth-day postpartum, the univariate analysis showed
that patients in the ARF group received more frequently
tranexamic acid (54% vs 38% in the non-ARF group;
p = 0.03), diuretics (p = 0.006), and concentrated serum
albumin (p = 0.0012) (Table 5). Of note, 83% of patients
with postpartum hemorrhage in the ARF group received
tranexamic acid (mean dose: 5 ± 4.84 g).
The amount of packed red cells, platelets, fibrinogen,
and other plasma substitutes was not different. Seven pa-
tients received recombinant activated factor seven. Four
of these seven patients presented an acute renal failure,
one in the ARF group 1, one in the ARF group 2, and two
in the ARF group 3.
In the multivariate analysis of risk factors for ARF, the
following variables were not significant: postpartum
hemorrhage, preeclampsia, HELLP, ISTH of >3, and
use of tranexamic acid. The only independent risk factors
identified were the association of postpartum hemorrhage
with the HELLP syndrome (OR [CI 95%] = 4.1 [1.75 to
9.66]; p = 0.0012) and the administration of 20% hyperon-
cotic serum albumin (OR [CI 95%] = 3.34 [1.47 to 7.60];
p = 0.0039).
Discussion
In our study, ARF occurred in 37% of patients admitted
to ICU and 29% of them required dialysis. In 12% of the
cases, ARF evolved into chronic kidney disease due to
cortical necrosis. The frequency of ARF clearly dependson the cutoff level of blood creatinine used to define
renal failure. We chose in our study a cutoff blood cre-
atinine level of 89 μmol/L according to French recom-
mendations [19]. During pregnancy, physiological changes
in renal blood flow and glomerular filtration rate induce a
lower level of blood creatinine so that cutoff levels of the
general population are not reliable. A worldwide definition
of criteria in pregnant women could help to better com-
pare studies of ARF. Our study certainly overestimates
the incidence of severe cases of ARF as we focalized on
an ICU setting. However, an increase in the incidence of
severe ARF in developed countries was recently docu-
mented in studies from Canada [20]. It might be related
to demographic changes such as increased age, obesity,
caesarian section [21], incidence of preeclampsia [22] or
postpartum hemorrhage, and their treatments. This was
also documented in two recent studies in Australia and
Canada [23,24].
Our data suggest that postpartum hemorrhage and
HELLP syndrome are common causes of ARF and their
combination an independent risk factor of its occurrence.
Gurrieri et al. identified 55 cases of ARF over a 5-year
period, seven of which were related to HELLP syndrome
[25]. Sibai et al. in 1993 documented an incidence of ARF
of 7.4% among HELLP syndrome patients, 31% of which
required dialysis [26], but the association of postpartum
hemorrhage with the HELLP syndrome was not docu-
mented in these studies.
Our study provides evidence that HELLP syndrome in
combination with postpartum hemorrhage is an important
factor for occurrence of ARF. The pathophysiologic
Table 5 Frequency of ARF according to the type and dose of treatments
ARF group n = 68 No ARF group n = 114 p value
Crystalloids
n = 121 52 (93) 69 (84) 0.12
mLa 2,000 [1,500 to 3,000] 2,000 [1,000 to 2,500] 0.58
Artificial colloids
n = 100 40 (74) 60 (71) 0.7
mLa 1,000 [1,000 to 1,750] 1,000 [1,000 to 2,000] 0.66
Hyperoncotic albumin
n = 32 20 (29) 12 (10) 0.0012
mLa 250 [200 to 400] 200 [200 to 300] 0.52
Albumin 4%
n = 24 8 (12) 16 (14) 0.66
mLa 750 [500 to 1,375] 750 [500 to 1,000] 0.94
Packed red cells
n = 107 44 (65) 63 (56) 0.26
mLa 800 [600 to 120] 1,000 [600 to 1,600] 0.11
Platelets concentrates
n = 68 25 (38) 43 (38) 0.94
na 1 [1 to 2] 1 [1 to 2] 0.55
Fresh frozen plasma (FFP)
n = 94 37 (56) 57 (51) 0.54
na 4 [3 to 6] 5 [3 to 7] 0.11
Fibrinogen concentrate
n = 107 45 (66) 62 (57) 0.24
ga 4.50 [3 to 7.5] 5.5 [3 to 7.5] 0.75
Activated factor VII
n = 7 4 (6) 3 (3) NA
Tranexamic acid
n = 79 37 (54) 42 (38) 0.03
ga 5 [4 to 7] 5 [3 to 9] 0.66
Antihypertensive drugs in ICU
n = 101 43 (64) 58 (52) 0.10
na 1 [0 to 3] 1 [0 to 2] 0.03
Diuretics
n = 73 36 (53) 37 (32) 0.006
ACE inhibitors
n = 50 24 (35) 26 (23) 0.079
Radio-contrast media
n = 27 11 (16) 16 (14) 0.71
Aminoglycosides
n = 33 12 (18) 21 (19) 0.87
Data are N (%) for qualitative variables. Frequency is given in brackets considering missing data. aQuantitative variables are presented as median [space interquartile
range: 25th to 75th percentiles]. mL: milliter; n: number; g: grams; NA = not applicable.
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Table 6 Characteristics and comparisons of the 30 patients with HELLP associated to PPH
ARF group n = 20 No ARF group n = 10 p value
Baseline characteristics
Age, yearsa 32 [27 to 35] 29 [24 to 32] 0.1
Number of pregnancya 2.5 [1 to 3] 1.5 [1 to 3] 0.45
Paritya 2 [1 to 3] 1 [1 to 2] 0.45
Terma (weeks of gestation) 37 [36 to 39] 37 [32 to 38] NA
Twin gestation n = 3 2 (10) 1 (10) NA
Obesity n = 8 6 (30) 2 (20) NA
Chronic hypertension n = 2 2 (10) 0 NA
Gestational hypertension n = 4 4 (20) 0 NA
Gestational diabetes n = 8 6 (30) 2 (20) NA
Antihypertensive drugs before pregnancy n = 1 1 (5) 0 NA
Antihypertensive drugs during pregnancy n = 9 6 (30) 3 (30) NA
SAPS II scorea 31 [22 to 39] 15 [12 to 23.5] 0.01
Length of stay in the ICUa (day) 5.5 [4 to 10] 3 [2 to 4] 0.04
Complications of delivery
PPH secondary to HELLP n = 28 18 (90) 10 (100) 0.3
Postpartum HELLP secondary to PPH n = 2 2 (10) 0 NA
Volume of bleedinga mL 1,600 [1,050 to 2,100] 2100 [975–3175] 0.6
Hypotension n = 7 4 (20) 3 (30) 0.4
ISTH >3 n = 17 11 (55) 6 (60) 0.4
Treatments
Crystalloids
n = 22 16 (80) 6 (60) 0.38
mLa 2,500 [1,500 to 3,000] 2,500 [2,000 to 2,625] 0.9
Artificial colloids
n = 21 15 (75) 6 (60) 0.43
mLa 1,000 [1,000 to 1,500] 1,250 [500 to 1,625] 0.8
Hyperoncotic albumin
n = 8 6 (30) 2 (20) 0.68
mLa 250 [200 to 400] 300 [300 to 400] 0.22
4% albumin
n = 8 6 (30) 2 (20) 0.68
mLa 750 [437 to 1,812] 750 [500 to 750] 0.86
Packed red cells
n = 24 16 (80) 8 (80) NA
mLa 700 [450 to 1,150] 800 [450 to 1,150] 0.9
Platelets concentrates
n = 14 9 (45) 5 (50) 0.8
na 1 [1 to 1.5] 1 [1 to 2] 0.09
Fresh frozen plasma
n = 16 10 (50) 6 (60) 0.6
na 5 [2.7 to 6.2] 2.5 [2 to 4.2] 0.09
Jonard et al. Annals of Intensive Care 2014, 4:36 Page 8 of 11
http://www.annalsofintensivecare.com/content/4/1/36
Table 6 Characteristics and comparisons of the 30 patients with HELLP associated to PPH (Continued)
Fibrinogen concentrates
n = 25 17 (85) 8 (80) NA
ga 4.5 [3 to 8] 3 [2 to 7] 0.23
Activated factor VII
n = 1 1 (5) 0 NA
Tranexamic acid
n = 19 16 (80) 3 (30) 0.01
ga 5.5 [3.6 to 6.7] 5 [4 to 5] 0.6
Antihypertensive drugs in ICU
n = 25 17 (85) 8 (80) NA
Diuretics
n = 16 12 (60) 4 (40) 0.3
ACE inhibitors
n = 14 10 (50) 4 (40) 0.6
Radio-contrast media
n = 3 0 3 (30) NA
Aminoglycosides
n = 1 1 (5) 0 NA
Data are N (%) for qualitative variables. Incidence is given in brackets considering missing data. Concerning treatments, the incidence is related to the number of
patients who actually received the treatment. aQuantitative variables are presented as median [space interquartile range: 25th to 75th percentiles]. mL: milliter;
n: number; g: grams; NA = not applicable.
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mented in our study, except in women who did not re-
cover and developed a cortical necrosis. Usually, acute
tubular necrosis is considered the most frequent histo-
logical lesion found in women suffering from HELLP syn-
drome and acute kidney injury. In our study, the HELLP
syndrome mostly preceded the postpartum hemorrhagic
complication. It can be hypothesized that the HELLP-
induced thrombotic microangiopathy and hemolysis could
induce a first shot phenomenon of tubular ischemia, se-
quentially aggravated by postpartum haemorrhage. How-
ever, we were unable to document that the sequential
combination induced a more frequent arterial hypotension
or a higher amount of blood loss that could aggravate kid-
ney hypoperfusion. The first point should be considered
with caution since in our study we used a cutoff level of
60 mmHg to define arterial hypotension. Recent guide-
lines have defined a higher a 70 mmHg level to document
arterial hypotension in pregnant women. Regarding the
role of acute hemorrhage in the occurrence of ARF, there
was even a trend to lower blood loss in women suffering
from HELLP syndrome and postpartum hemorrhage com-
pared to isolated postpartum hemorrhage.
We also tried to document the potential role of coagu-
lation disorders in the occurrence of ARF. As measured
by the ISTH score, the incidence of overt DIC was low
and there was only a trend to higher ISTH score in pa-
tients combining postpartum hemorrhage and HELLPsyndrome. From a theoretical point of view, except in
overt DIC, the procoagulant state induced by the HELLP
syndrome could reduce the amount of hemorrhage. Due
to the low number of cases, this hypothesis cannot be
documented in our study. It seems more likely that the
addition of thrombotic microangiopathy induced by the
HELLP syndrome with hypovolemia and vasoconstric-
tion induced by hemorrhage could ‘synergistically’ com-
promise both placental and kidney perfusion.
Our study was the first to analyze the impact of treat-
ment. Hyperoncotic serum albumin was associated with
ARF whereas 4% albumin had no impact. This is in ac-
cordance with previously published data in other settings.
Preeclampsia may induce a hypovolemic state caused by
hypoalbuminemia and capillary permeability dysfunction.
The degree of hypovolemia increases significantly at the
ascitis state. Albumin is often used in that situation al-
though it has never demonstrated any benefit in terms of
maternal or fetal morbidity [27,28]. Outside of pregnancy,
the use of hyperoncotic albumin seemed associated with
development of acute renal failure [29]. The inferred mech-
anisms are the decrease in filtration pressure and a direct
nephrotoxicity. Further studies are required to clarify that
point in the postpartum setting.
Regarding haemostatic treatments used for postpartum
hemorrhage, ARF was significantly associated to tranex-
amic acid in the univariate analysis. This could be due to
a bias, since most patients whose postpartum course was
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hibitor. From a physiological point of view, pregnancy is
characterized by the progressive development of a pro-
coagulant and antifibrinolytic state. Delivery is character-
ized by an acute and transient fibrinolysis due to the loss
of the placental inhibitor of plasminogen activator and
exacerbated by placental ischemia or uterine atony. Tran-
examic acid binds in an irreversible fashion a lysine resi-
due on plasminogen, preventing it from binding fibrin and
tissue-plasminogen activator. Thus, blockade of fibrinoly-
sis by tranexamic acid is used to reduce the severity and
duration of postpartum hemorrhage. The possibility must
also be considered that by increasing intravascular coagu-
lation and renal ischemia, inhibition of fibrinolysis may
lead to ARF and cortical necrosis in these situations. From
a clinical perspective, the prophylactic use of tranexamic
acid has been shown to reduce postpartum hemorrhage in
three randomized clinical trials. Nevertheless, these stud-
ies were not powered to detect its impact on mortality,
the frequency of hysterectomy, and thromboembolic com-
plications [30]. There is no study regarding the use of
tranexamic acid in a curative intent and its possible ad-
verse effects on renal function. The possibility must be
considered that adding insult to injury, antifibrinolytic
drugs given to patients with a preexisting activated endo-
thelium by HELLP syndrome may increase the risk of
renal failure. In our study, 80% of the 20 patients who de-
veloped an ARF after the sequential occurrence of HELLP
syndrome and postpartum hemorrhage had received tran-
examic acid vs 30% only of those who did not develop
ARF. Additionally, seven among the eight patients who
developed chronic renal failure and cortical necrosis had
received tranexamic acid. The incidence of cortical necro-
sis was evaluated by Leidmer et al. [31] to approximately
1/80,000 whereas our study has identified seven cases out
182, proved by renal biopsy or MRI over a 5-year period
(3.8%). Recently, 12 cases of cortical necrosis following
postpartum hemorrhage treated with tranexamic acid and
associated with HELLP syndrome were reported by ne-
phrologists to alert the national health authorities. [32]. In
our study, the use of tranexamic acid was not documented
as an independent risk factor in the multivariate bootstrap
analysis, but taken together, these findings suggest that inhib-
ition of fibrinolysis should be used with caution in women
developing postpartum hemorrhage. The WOMAN study
currently ongoing will assess the impact of tranexamic
acid on the reduction of postpartum hemorrhage related
to mortality and hysterectomy and give us additional infor-
mation regarding the renal adverse effects of this drug [33].
Limits of our study
Our multicenter study was conducted in only three ICUs
in the north of France and included a limited number of
cases thus hindering interpretation of data. All ourpatients were admitted in tertiary-care ICU and severely
ill. This may introduce bias in the reported incidence and
outcome of complications. It is highly possible that we
could miss some patients developing an acute and rapidly
resolving mild renal failure in the postpartum period.
Additionally, given the nature of this study, we were
only able to identify factors strongly associated with ARF
and our study could not document the cause-effect rela-
tionships between these factors and ARF. However, in this
quite homogeneous population, we could perform an in-
dependent and exhaustive analysis of postpartum compli-
cations and of the potential role of treatments.
Conclusions
Our study suggests that among pregnancy-related dis-
eases, HELLP syndrome, when associated with postpar-
tum hemorrhage, induces the highest risk of ARF. Our
data do not support the possibility that this could be
due to higher blood loss or more severe coagulation
changes induced by the association. In these predisposed
patients, some treatments such as hyper-oncotic serum al-
bumin may be damageable for kidney function. A strong
attention should be given to kidney function and the use
of treatments at risk should be avoided.
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